SSR 411298

Drug Profile

SSR 411298

Alternative Names: SSR411298

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi; sanofi-aventis
  • Class Antidepressants; Anxiolytics
  • Mechanism of Action Fatty acid amide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Phase Unknown Cancer pain
  • No development reported Anxiety disorders
  • Discontinued Depressive disorders

Most Recent Events

  • 28 Feb 2011 No development reported - Phase-I for Anxiety disorders in France (PO)
  • 28 Feb 2010 Sanofi-aventis completes a phase II trial in depressive disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top